

UNITED STATES EPARTMENT OF COMMERCE United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		A	TORNEY DOCKET NO.
09/589,777	06/08/00	SUKHATME		٧	1440.1023-01
-			\neg	EXAMINER	
		HM12/0523	,		
DOREEN M H	OGLE ESQ			DAVIS.	Ν
HAMILTON B	ROOK SMITH 8	REYNOLDS PC		ART UNIT	PAPER NUMBER
TWO MILITIA DRIVE LEXINGTON MA 02421-4799				1642	Q
				DATE MAILED:	
					05/23/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231

APPLICATION NO. CONTROL NO.

FILING DATE

FIRST NAMED INVENTOR / PATENT IN REEXAMINATION

ATTORNEY DOCKET NO.

09/589777

EXAMINER	

ART UNIT

PAPER

DATE MAILED:

PI ase find below and/or attached an Office communication concerning this application or pr ceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the one month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed Natalie Davis whose telephone number is 703-308-6410.

GEETHAP BANSAL

PTO-90C (Rev.3-98)

Application/Control Number: 09/589,777

Art Unit: 1642

Specification

- 1. The application fails to comply with the sequence requirements of 37 C.F.R. 1.821-1.825, as claims 3 and 4 do not have required SEQ ID NO:. According to 37 C.F.R. 1.821 a nucleotide and /or amino acid sequences are interpreted to mean an unbranched sequence of four or more amino acids or an unbranched sequence of ten or more nucleotides. Applicant must make the following corrections according to 37 C.F.R. 1.821 (d), which states: where the description or claims of a patent application discuss a sequence that is set forth in the "Sequence Listing" in accordance with paragraph (c), reference must be made to the sequence by use of the sequence identifier, preceded by "SEQ ID NO:" in the text of the description or claims, even if the sequence is also embedded in the text of the description or claims of the patent application.
- 2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Natalie A Davis whose telephone number is 703-308-6410. The examiner can normally be reached on M-F 8-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached on 703-308-3995. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4315 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Natalie A. Davis May 21, 2001

PRIMARY EXAMINER

	Application No.					
	Application No. O9/589777					
Notice to Comply	<u>U7/387777</u> Examiner	Art Unit				
		Accome				
NOTICE TO COMPLY WITH REQU	JIREMENTS FOR PATEN	T APPLICATIONS				
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES						
·		•				
Applicant must file the items indicated below is attached to avoid abandonment under 3 provisions of 37 CFR 1.136(a)).	ow within the time period set the 5 U.S.C. § 133 (extensions of tir	Office action to which the Notice ne may be obtained under the				
The nucleotide and/or amino acid sequence the requirements for such a disclosure as s	e disclosure contained in this ap set forth in 37 C.F.R. 1.821 - 1.8	pplication does not comply with 25 for the following reason(s):				
1. This application clearly fails to comp attention is directed to the final rulemak OG 29 (May 15, 1990). If the effective notice published at 63 FR 29620 (June	king notice published at 55 FR 1 filing date is on or after July 1-1	8230 (May 1, 1990), and 1114				
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).						
3. A copy of the "Sequence Listing" in c 37 C.F.R. 1.821(e).	computer readable form has not	been submitted as required by				
4. A copy of the "Sequence Listing" in a content of the computer readable form 1.823, as indicated on the attached copy	does not comply with the require	ements of 37 C.F.R. 1,822 and/or				
5. The computer readable form that has and/or unreadable as indicated on the a readable form must be submitted as red	attached CRF Diskette Problem	has been found to be damaged Report. A Substitute computer				
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).						
7. Other:						
Applicant Must Provide: An initial or substitute computer readable	le form (CRF) copy of the "Sequ	ence Listing".				
An initial or substitute paper copy of the into the specification.	"Sequence Listing", as well as a	an amendment directing its entry				
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).						
For questions regarding compliance	to these requirements, plea	ase contact:				
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 PatentIn Software Program Support						
Technical Assistance	700 007 000	NO.				

To Purchase Patentin Software......703-306-2600
PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY